vs

Side-by-side financial comparison of i3 Verticals, Inc. (IIIV) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $52.7M, roughly 1.4× i3 Verticals, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -14.6%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $13.8M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -4.7%).

The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

IIIV vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.4× larger
PBYI
$75.5M
$52.7M
IIIV
Growing faster (revenue YoY)
PBYI
PBYI
+42.3% gap
PBYI
27.7%
-14.6%
IIIV
More free cash flow
PBYI
PBYI
$575.0K more FCF
PBYI
$14.4M
$13.8M
IIIV
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-4.7%
IIIV

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IIIV
IIIV
PBYI
PBYI
Revenue
$52.7M
$75.5M
Net Profit
$484.0K
Gross Margin
69.3%
Operating Margin
3.1%
22.7%
Net Margin
0.9%
Revenue YoY
-14.6%
27.7%
Net Profit YoY
-76.5%
EPS (diluted)
$0.02
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IIIV
IIIV
PBYI
PBYI
Q4 25
$52.7M
$75.5M
Q3 25
$46.0M
$54.5M
Q2 25
$51.9M
$52.4M
Q1 25
$63.1M
$46.0M
Q4 24
$52.2M
$59.1M
Q3 24
$32.0M
$80.5M
Q2 24
$46.2M
$47.1M
Q1 24
$58.0M
$43.8M
Net Profit
IIIV
IIIV
PBYI
PBYI
Q4 25
$484.0K
Q3 25
$3.1M
$8.8M
Q2 25
$12.9M
$5.9M
Q1 25
$-154.0K
$3.0M
Q4 24
$2.1M
Q3 24
$117.9M
$20.3M
Q2 24
$-7.5M
$-4.5M
Q1 24
$1.9M
$-4.8M
Gross Margin
IIIV
IIIV
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
IIIV
IIIV
PBYI
PBYI
Q4 25
3.1%
22.7%
Q3 25
3.2%
17.6%
Q2 25
-9.3%
12.7%
Q1 25
8.0%
8.7%
Q4 24
3.9%
22.6%
Q3 24
10.6%
27.4%
Q2 24
-2.8%
-4.6%
Q1 24
3.4%
-5.3%
Net Margin
IIIV
IIIV
PBYI
PBYI
Q4 25
0.9%
Q3 25
6.7%
16.2%
Q2 25
24.8%
11.2%
Q1 25
-0.2%
6.5%
Q4 24
3.9%
Q3 24
368.2%
25.2%
Q2 24
-16.3%
-9.6%
Q1 24
3.2%
-11.0%
EPS (diluted)
IIIV
IIIV
PBYI
PBYI
Q4 25
$0.02
$0.26
Q3 25
$0.14
$0.17
Q2 25
$0.50
$0.12
Q1 25
$0.00
$0.06
Q4 24
$0.08
$0.40
Q3 24
$4.93
$0.41
Q2 24
$-0.32
$-0.09
Q1 24
$0.08
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IIIV
IIIV
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$37.5M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$358.5M
$130.3M
Total Assets
$595.9M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IIIV
IIIV
PBYI
PBYI
Q4 25
$37.5M
$97.5M
Q3 25
$66.7M
$94.4M
Q2 25
$55.5M
$96.0M
Q1 25
$7.7M
$93.2M
Q4 24
$85.6M
$101.0M
Q3 24
$86.5M
$96.7M
Q2 24
$9.7M
$96.8M
Q1 24
$3.1M
$107.2M
Total Debt
IIIV
IIIV
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$0
$34.0M
Q2 25
$0
$45.3M
Q1 25
$12.0M
$56.7M
Q4 24
$26.2M
$68.0M
Q3 24
$26.2M
$79.3M
Q2 24
$374.1M
$90.7M
Q1 24
$369.6M
$102.0M
Stockholders' Equity
IIIV
IIIV
PBYI
PBYI
Q4 25
$358.5M
$130.3M
Q3 25
$389.6M
$115.3M
Q2 25
$383.3M
$104.7M
Q1 25
$385.2M
$97.1M
Q4 24
$375.0M
$92.1M
Q3 24
$379.7M
$71.1M
Q2 24
$249.7M
$48.5M
Q1 24
$249.3M
$51.0M
Total Assets
IIIV
IIIV
PBYI
PBYI
Q4 25
$595.9M
$216.3M
Q3 25
$638.4M
$202.9M
Q2 25
$623.3M
$194.9M
Q1 25
$646.4M
$196.2M
Q4 24
$726.2M
$213.3M
Q3 24
$730.7M
$220.7M
Q2 24
$861.7M
$205.0M
Q1 24
$625.8M
$214.1M
Debt / Equity
IIIV
IIIV
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.00×
0.30×
Q2 25
0.00×
0.43×
Q1 25
0.03×
0.58×
Q4 24
0.07×
0.74×
Q3 24
0.07×
1.12×
Q2 24
1.50×
1.87×
Q1 24
1.48×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IIIV
IIIV
PBYI
PBYI
Operating Cash FlowLast quarter
$14.1M
$14.4M
Free Cash FlowOCF − Capex
$13.8M
$14.4M
FCF MarginFCF / Revenue
26.2%
19.1%
Capex IntensityCapex / Revenue
0.6%
0.0%
Cash ConversionOCF / Net Profit
29.18×
TTM Free Cash FlowTrailing 4 quarters
$6.5M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IIIV
IIIV
PBYI
PBYI
Q4 25
$14.1M
$14.4M
Q3 25
$14.0M
$9.7M
Q2 25
$7.4M
$14.1M
Q1 25
$-27.1M
$3.6M
Q4 24
$11.5M
$15.6M
Q3 24
$15.1M
$11.0M
Q2 24
$8.1M
$1.0M
Q1 24
$10.7M
$11.2M
Free Cash Flow
IIIV
IIIV
PBYI
PBYI
Q4 25
$13.8M
$14.4M
Q3 25
$13.5M
$9.7M
Q2 25
$6.8M
$14.1M
Q1 25
$-27.6M
$3.6M
Q4 24
$11.0M
$15.6M
Q3 24
$14.6M
$11.0M
Q2 24
$7.2M
$1.0M
Q1 24
$9.9M
FCF Margin
IIIV
IIIV
PBYI
PBYI
Q4 25
26.2%
19.1%
Q3 25
29.5%
17.7%
Q2 25
13.1%
26.8%
Q1 25
-43.8%
7.7%
Q4 24
21.1%
26.4%
Q3 24
45.6%
13.7%
Q2 24
15.6%
2.1%
Q1 24
17.1%
Capex Intensity
IIIV
IIIV
PBYI
PBYI
Q4 25
0.6%
0.0%
Q3 25
0.9%
0.0%
Q2 25
1.0%
0.0%
Q1 25
0.8%
0.1%
Q4 24
0.9%
0.0%
Q3 24
1.7%
0.0%
Q2 24
1.9%
0.0%
Q1 24
1.4%
0.0%
Cash Conversion
IIIV
IIIV
PBYI
PBYI
Q4 25
29.18×
Q3 25
4.52×
1.10×
Q2 25
0.57×
2.41×
Q1 25
1.21×
Q4 24
5.59×
Q3 24
0.13×
0.54×
Q2 24
Q1 24
5.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IIIV
IIIV

License And Service$35.7M68%
Proprietary Payments Revenue$14.5M27%
Other Revenue$2.5M5%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons